津  药  太  平  医  药  有  限  公  司

Jinyao Pacific Pharmaceutical Co., Ltd.

Jinyao PacificPharmaceutical Co., Ltd. (hereinafter referred to as "JinyaoPacific") is an enterprise in the pharmaceutical distribution andwholesale sector of Tianjin Pharmaceutical Holdings Group. It is one of theleading pharmaceutical commercial enterprises in Tianjin and a benchmarkenterprise in pharmaceutical distribution across northern coastal cities inChina's open economic zones. The company has a registered capital of RMB 1billion, total assets of nearly RMB 7 billion and annual operating revenue ofnearly RMB 10 billion as of the end of 2024.

Withorigins tracing back to the state-owned Tianjin Pharmaceutical Companyestablished in 1950, the company has undergone four key transformations: it wasrestructured into a Sino-foreign joint venture in 1994, converted into adomestically funded limited liability company in 2005, renamed TianjinPharmaceutical Group Taiping Pharmaceutical Co., Ltd. in 2008, and officiallydesignated as Jinyao Pacific Pharmaceutical Co., Ltd. in 2023. Over more than70 years of sustained development, the company has consistently kept pace withChina's pharmaceutical and healthcare industry.

As a benchmark for industry credibility, Jinyao Pacific wasrecognized in 2009 by the Ministry of Commerce as one of the first batch of"National AAA-Level Credit Enterprises in Pharmaceutical Commerce",thanks to its rigorous quality management and standardized operations. Thecompany has been consistently ranked among the Top 100 pharmaceuticalcirculation and wholesale enterprises for many years and has been designated bythe Tianjin Municipal Government as a strategic and emergency pharmaceuticalreserve base, undertaking the core mission of safeguarding regionalpharmaceutical supply. Its business scope covers a full range of pharmaceuticalproducts, including proprietary Chinese medicines, chemical raw materials andtheir formulations, antibiotics, biological products, diagnostic drugs,narcotic drugs, and medical devices, comprehensively meeting the needs ofmedical terminals and market demand.

Interms of channel layout and logistics capabilities, Jinyao Pacific has built anextensive and highly coordinated operational network. The company isheadquartered in Tianjin and comprises 5 business centers and 14 functionaldepartments, overseeing 18 branch companies, 7 wholly-owned subsidiaries, 4 controlledsubsidiaries, and 8 pharmacies (including 5 specialized DTP pharmacies). Itssales network covers all 16 administrative districts of Tianjin, reaching bothpublic and private healthcare institutions, over-the-counter (OTC) markets, ande-commerce platforms—achieving "comprehensive coverage without blind spots".Regarding logistics, the company owns 3 warehouse facilities and modernlogistics centers, with a total storage area of nearly 43,000 m². Thesefacilities are fully equipped with GSP-compliant systems and equipment,including automated temperature and humidity monitoring systems, professionalinsulated containers, and refrigerated transport fleets. Notably, the modernpharmaceutical logistics center located in Beichen District integrates advancedlogistics infrastructure, warehouse management systems, and information networktechnologies to streamline operations previously dispersed across differentdepartments, processes, and operational stages—maximizing operationalefficiency and minimizing costs. Through technological innovation, the companyhas secured national software copyright for its "RefrigeratedTransportation Temperature Monitoring and Recording System" and obtained anational utility model patent for "A Pharmaceutical Insulated Containerand Its Monitoring System". It has also passed multiple evaluations andaudits by international authoritative bodies such as SGS and has beenconsecutively awarded the "National First Prize for Excellent QualityManagement QC Group Achievement Presentation in the Pharmaceutical Industry",demonstrating its robust capabilities in safeguarding pharmaceutical logisticssafety.

Innovationis the core engine driving Jinyao Pacific's development. As a pioneer inhospital Supply-Processing-Distribution (SPD) cooperation and the extendedpharmaceutical logistics management model in China, the company has ledindustry innovation since 2011. It has established deep partnerships with 20hospitals and developed and refined both the "Basic SPD Model" andthe "Dual-Terminal SPD Model". By enabling direct drug delivery tooutpatient departments and central pharmacy stations, it innovatively launchedthe "outpatient zero-inventory management" mechanism, enablingsimultaneous supply from multiple vendors and effectively resolving pain pointsin in-hospital pharmaceutical circulation. For these achievements, the companyreceived the "National Best Logistics Innovation Award", providingthe pharmaceutical distribution industry with a replicable "PacificSolution" for digital and intensive transformation.

Guidedby its corporate spirit—"Integrity First, Health Protection, Always MovingForward"—Jinyao Pacific has consistently upheld its strong sense of socialresponsibility. As a core participant in government-led industry research andcollaboration initiatives, the company actively serves as a compliant liaisonbetween hospitals and manufacturers, fostering the healthy development of thepharmaceutical industry ecosystem. During the COVID-19 pandemic, the companyacted swiftly to allocate epidemic prevention supplies and successfullycompleted the Tianjin municipal government's assigned task of distributing andtransporting such materials. Through concrete actions, it has embodied itscorporate commitment, earning high recognition from government departments atall levels and all sectors of society.

Lookingahead, Jinyao Pacific will continue to deepen its innovative philosophy ofextending pharmaceutical logistics services to healthcare providers andpatients through a new model. Leveraging its well-established network layout,leading-edge logistics technology, and stringent quality control systems, thecompany will collaborate with partners across the industrial chain to pursuemutual development and make greater contributions to advancing nationalhealthcare reform and safeguarding public health and well-being.